Your browser doesn't support javascript.
loading
Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial.
Chong, Wan-Qin; Mogro, Maria Jannet; Arsad, Asrie; Tai, Bee-Choo; Lee, Soo-Chin.
  • Chong WQ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, 1E Lower Kent Ridge Road, Singapore, 119228, Singapore. wan_qin_chong@nuhs.edu.sg.
  • Mogro MJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, 1E Lower Kent Ridge Road, Singapore, 119228, Singapore.
  • Arsad A; Department of Medicine, National University Hospital, Singapore, Singapore.
  • Tai BC; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • Lee SC; Department of Haematology-Oncology, National University Cancer Institute, Singapore, 1E Lower Kent Ridge Road, Singapore, 119228, Singapore.
Support Care Cancer ; 29(7): 3689-3696, 2021 Jul.
Article en En | MEDLINE | ID: mdl-33188612
ABSTRACT

PURPOSE:

Complementary and alternative medicine (CAM) is often used by cancer patients and is concerning as concomitant oral CAM and chemotherapy use may result in adverse interactions and toxicities. We hypothesise that a decision aid (DA) may promote informed and rational use of oral CAM during chemotherapy, and increase patients' discussion with their oncologists on CAM use.

METHODS:

We randomised 240 patients initiating chemotherapy to receive DA or none. Questionnaires were administered at randomisation (visit 1), 1 month (visit 2) and 3 months (visit 3). The primary endpoint was the decisional conflict score (DCS) for decision made on CAM use during chemotherapy. Secondary endpoints include patients' decision regret score (DRS) on CAM use, CAM uptake, discussion with oncologists on CAM usage, and difference in quality of life (QoL) score between CAM and non-CAM users at visit 3.

RESULTS:

There was no difference in the mean DCS (mean difference 2.7 [95 CI - 2.9 to 8.3, p = 0.345]) and DRS (mean difference - 0.3 [95% CI - 6.3 to 5.8, p = 0.926]) between the two arms. There was a reduction in odds of CAM usage in the intervention arm compared to control arm (OR = 0.36, 95% CI 0.17 to 0.78, p = 0.009), but there was no difference in discussion with oncologists on CAM usage (OR = 0.46, 95% CI 0.07 to 3.01, p = 0.419), or in the QoL between CAM and non-CAM users.

CONCLUSION:

Our DA did not reduce DCS among cancer patients on chemotherapy. DA that provides more evidence-based information on CAM, and non-judgemental discussion initiated by oncologists to discuss CAM, may improve its effectiveness.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Médicos / Calidad de Vida / Terapias Complementarias / Técnicas de Apoyo para la Decisión / Toma de Decisiones / Neoplasias Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Qualitative_research Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Médicos / Calidad de Vida / Terapias Complementarias / Técnicas de Apoyo para la Decisión / Toma de Decisiones / Neoplasias Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Qualitative_research Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article